Compare Novo Nordisk A/S (NVO) vs J M Smucker Co (SJM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs J M Smucker Co — how do they compare? Novo Nordisk A/S trades at $44.91 (market cap $200.69B), while J M Smucker Co trades at $123.61 (market cap $13.32B). The key difference: Novo Nordisk A/S is far larger — about 15.1× J M Smucker Co's market cap, and Novo Nordisk A/S pays the higher dividend (3.98%). Which is the better fit depends on your goals.
| NVO | SJM | |
|---|---|---|
Market Cap | $200.69B | $13.32B |
Sector | Health | Consumer Staples |
52-Week High | $63.98 | $132.34 |
52-Week Low | $35.29 | $89.53 |
Enterprise Value | $215.49B | $20.17B |
Dividend Yield | 3.98% | 3.59% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novo Nordisk (NVO) trades at $45.16, down 3.09% today, with bearish technical signals but strong fundamentals. The stock shows robust profitability with 35.35% net margin and 59.82% ROE, supported by consistent earnings beats. Recent developments include positive pediatric obesity trial results for semaglutide and Wegovy pill launch in Germany. Cash flow remains healthy with $10.81B net inflow in 2025, though 2026 projections show a decline.
NVO presents a mixed outlook with strong fundamental metrics offset by technical weakness and competitive pressures. Investment opportunity lies in the expanding GLP-1 market and pipeline developments, while risks include market share loss to Eli Lilly and failed cardiovascular drug trials. Analyst consensus leans bullish with 57.9% buy ratings, but recent prescription slowdown concerns warrant caution.
SJM trades at $124.66, down 1.13% on the day, with a bullish technical signal per moving averages despite oscillators showing bearish momentum. The company reported strong Q1 2027 earnings, beating estimates with EPS of $3.24, and raised full-year guidance. Valuation metrics include a P/E of 58.25 and P/S of 1.45, while recent news highlights CEO and CFO stock sales and positive analyst sentiment.
Outlook is positive with a consensus price target of $144.78, implying 16% upside, supported by earnings momentum and dividend yield. Risks include high debt levels, with debt-to-asset ratio at 43.71% in 2025, and volatile net income margins, which turned negative in 2025. Investors should weigh strong recent performance against financial leverage and insider selling activity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About J M Smucker Co
J.M. Smucker is a packaged food company that primarily operates in the U.S. retail channel (87% of fiscal 2022 revenue), but also in U.S. food-service (7%), and international (6%). Its largest segment is pet food and treats (36% of 2022 revenue), with popular brands such as Milk-Bone, Meow Mix, 9Lives, Kibbles 'n Bits, Nature's Recipe, and Rachael Ray Nutrish. Its second-largest category is coffee (35% across channels) with the number-two brand Folgers and number-six Dunkin'. Other large categories are peanut butter (10%), with number-one Jif, fruit spreads (5%) with number-one Smucker's, and frozen hand-held foods (6%) with number-one Uncrustables.
Read more on SJM →
